Drugs that contain Buprenorphine Hydrochloride; Naloxone Hydrochloride

1. List of Bunavail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US9655843 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US8703177 BDSI Abuse-resistant mucoadhesive devices for delivery of buprenorphine
Aug, 2032

(9 years from now)

US9522188 BDSI Abuse resistant transmucosal drug delivery device
Apr, 2035

(12 years from now)

Market Authorisation Date: 06 June, 2014

Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence

Dosage: FILM;BUCCAL

How can I launch a generic of BUNAVAIL before it's patent expiration?
More Information on Dosage

2. List of Suboxone drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9931305 INDIVIOR INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Feb, 2022

(11 months ago)

US9855221 INDIVIOR INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2022

(11 months ago)

US10285910 INDIVIOR INC Sublingual and buccal film compositions
Oct, 2022

(3 months ago)

US8017150 INDIVIOR INC Polyethylene oxide-based films and drug delivery systems made therefrom
Feb, 2023

(7 days from now)

US8603514 INDIVIOR INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(1 year, 1 month from now)

US11135216 INDIVIOR INC Sublingual and buccal film compositions
Aug, 2029

(6 years from now)

US9687454 INDIVIOR INC Sublingual and buccal film compositions
Aug, 2029

(6 years from now)

US8475832 INDIVIOR INC Sublingual and buccal film compositions
Mar, 2030

(7 years from now)

Market Authorisation Date: 30 August, 2010

Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence

Dosage: FILM;BUCCAL, SUBLINGUAL

How can I launch a generic of SUBOXONE before it's patent expiration?
More Information on Dosage

3. List of Zubsolv drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8658198 OREXO US INC Non-abusable pharmaceutical composition comprising opioids
Dec, 2027

(4 years from now)

US8470361 OREXO US INC Non-abusable pharmaceutical composition comprising opioids
May, 2030

(7 years from now)

US9259421 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US10874661 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US11433066 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US11020388 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US11020387 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US10946010 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US8940330 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US9439900 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

Market Authorisation Date: 03 July, 2013

Treatment: Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone; Use of zubsolv for treatment of opioid dependence

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of ZUBSOLV before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic